Nobivac® Feline 1-HCPCh

Feline Rhinotracheitis, Calici, Panleukopenia, Chlamydia Psittaci Vaccine, MODIFIED LIVE VIRUS AND CHLAMYDIA

Proven to protect against several important feline viruses as well as feline Chlamydophila.

Features and benefits

  • A quality 1-year core vaccine that protects against feline rhinotracheitis, feline panleukopenia (FPV), and feline calicivirus (FCV), plus protects against feline Chlamydophila.
  • Nobivac® Feline 1-HCP has been shown to block the replication of canine parvovirus (CPV) in cats1
    • Evidence shows that CPV-2a, CPV-2b, and CPV-2c isolates can replicate in cats, producing clinical signs of feline panleukopenia2–4
  • Goes beyond core antigen protection to help prevent feline Chlamydophila infection
  • Non-adjuvanted formula
  • Optimal for healthy outdoor cats or cats that board frequently


  • Approved for the vaccination of healthy cats as an aid in the prevention of disease caused by feline rhinotracheitis, calici, and panleukopenia viruses, and Chlamydia psittaci
  • Recommended for use in healthy cats 9 weeks of age or older

Safety information

Please see the product label for safety information.

Administration and Dosage

For cats 9 weeks of age or older:

  • Subcutaneous or intramuscular injection
  • Initial 1-mL dose administered at 9 weeks of age or older
  • Second 1-mL dose administered 3 to 4 weeks later
  • Annual revaccination with 1 dose is recommended

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


  1. Data on file, Merck Animal Health.
  2. Hoelzer K, Parrish CR. The emergence of parvoviruses of carnivores. Vet Res. 2010;41(6):39.
  3. Ikeda Y, Nakamura K, Miyazawa T, Takahashi E, Mochizuki M. Feline host range of canine parvovirus: recent emergence of new antigenic types in cats. Emerg Infect Dis. 2002;8(4):341–346.
  4. Truyen U. Emergence and recent evolution of canine parvovirus. Vet Microbiol. 1999;69(1–2):47–50.